News Thanks Mr President, but you’re wrong about FDA, says rare d... NORD patient advocacy group responds to Congress speech
News Kite’s CAR-T therapy most valuable pipeline orphan drug Drug tops list compiled by Evaluate Pharma
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
Views & Analysis Rare diseases and orphan drugs need digital innovation mHealth tech can provide longer-term monitoring for clinical trials.
News Biogen/Ionis could launch rare disease drug within weeks Companies prepare for launch of Spinraza after phase 3 success.
Views & Analysis Are European incentives speeding access in rare cancer treat... Examining the impact of support programmes for orphan treatments.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.